DBV Technologies

DBVTPhase 3

Bagneux, FranceFounded 2002dbv-technologies.com

DBV Technologies is a pioneer in epicutaneous immunotherapy, developing the VIASKIN® patch as a potential new class of treatment for food allergies and other immunological conditions. Its lead program, VIASKIN® Peanut (DBV712), has completed a Phase 3 trial in toddlers and has an ongoing Phase 3 trial in children aged 4-7, positioning it as a frontrunner in non-invasive allergy desensitization. The company is also advancing programs for cow's milk allergy and exploring broader applications in autoimmune diseases and vaccines, leveraging its unique platform technology.

Market Cap

$1.1B

Founded

2002

Focus

Small Molecules

DBVT · Stock Price

USD 19.09+15.93 (+504.11%)

Historical price data

AI Company Overview

Technology Platform

VIASKIN® epicutaneous immunotherapy (EPIT) platform, a patch-based technology designed to deliver minimal amounts of antigen through the skin to re-educate the immune system and induce tolerance.

Pipeline Snapshot

15 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
Viaskin Peanut 250mcg + Placebo	Peanut Allergy	Phase 3
Viaskin Peanut 250µg	Peanut Allergy	Phase 3
Part A Viaskin Peanut 250 mcg + Part A Viaskin Peanut 100 mcg + Part A Placebo +...	Peanut Allergy	Phase 3
DBV712 250 mcg	Peanut Allergy	Phase 3
Viaskin Peanut 250 mcg + Placebo	Peanut Allergy	Phase 3

Funding History

Total raised: $80M

PIPE$50MUndisclosedDec 15, 2015

IPOUndisclosedUndisclosedDec 7, 2012

Series B$20MUndisclosedJun 15, 2007

Series A$10MUndisclosedJun 15, 2002

Opportunities

The primary growth opportunity is the commercialization of VIASKIN® Peanut for the large pediatric peanut allergy market.

Further opportunities include expanding the EPIT platform to treat other food allergies (e.g., milk, egg), exploring applications in autoimmune/inflammatory diseases, and utilizing the skin delivery platform for novel vaccines.

Risk Factors

Key risks include the failure of the ongoing Phase 3 VITESSE trial to meet endpoints, regulatory challenges in gaining approval, competition from established oral immunotherapy, and the need for additional financing to fund operations and commercialization.

Competitive Landscape

DBV's main competitor is Aimmune Therapeutics (Nestlé), marketer of the oral immunotherapy PALFORZIA®. DBV differentiates through its epicutaneous (patch) delivery, which is designed to offer a superior safety and tolerability profile by minimizing systemic and gastrointestinal exposure compared to oral routes.

Publications

Patents

Pipeline